Our top pick for
TherapeuticsMD Inc is a drug manufacturers-specialty & generic business based in the US. TherapeuticsMD shares (TXMD) are listed on the NASDAQ and all prices are listed in US Dollars. TherapeuticsMD employs 400 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.79|
|52-week range||$0.67 - $2.65|
|50-day moving average||$0.74|
|200-day moving average||$1.03|
|Wall St. target price||$5.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.48|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||9.62%|
|1 month (2021-09-22)||12.17%|
|3 months (2021-07-22)||-25.47%|
|6 months (2021-04-22)||-35.77%|
|1 year (2020-10-22)||-48.03%|
|2 years (2019-10-22)||-78.99%|
|3 years (2018-10-22)||5.37|
|5 years (2016-10-21)||6.22|
|Revenue TTM||$84.8 million|
|Gross profit TTM||$48.9 million|
|Return on assets TTM||-37.26%|
|Return on equity TTM||0%|
|Market capitalisation||$305.4 million|
TTM: trailing 12 months
There are currently 28.9 million TherapeuticsMD shares held short by investors – that's known as TherapeuticsMD's "short interest". This figure is 0.7% up from 28.7 million last month.
There are a few different ways that this level of interest in shorting TherapeuticsMD shares can be evaluated.
TherapeuticsMD's "short interest ratio" (SIR) is the quantity of TherapeuticsMD shares currently shorted divided by the average quantity of TherapeuticsMD shares traded daily (recently around 5.5 million). TherapeuticsMD's SIR currently stands at 5.28. In other words for every 100,000 TherapeuticsMD shares traded daily on the market, roughly 5280 shares are currently held short.
However TherapeuticsMD's short interest can also be evaluated against the total number of TherapeuticsMD shares, or, against the total number of tradable TherapeuticsMD shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TherapeuticsMD's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 TherapeuticsMD shares in existence, roughly 70 shares are currently held short) or 0.0731% of the tradable shares (for every 100,000 tradable TherapeuticsMD shares, roughly 73 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against TherapeuticsMD.
Find out more about how you can short TherapeuticsMD stock.
We're not expecting TherapeuticsMD to pay a dividend over the next 12 months.
TherapeuticsMD's shares were split on a 1:100 basis on 2 October 2011. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TherapeuticsMD shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for TherapeuticsMD shares which in turn could have impacted TherapeuticsMD's share price.
Over the last 12 months, TherapeuticsMD's shares have ranged in value from as little as $0.67 up to $2.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TherapeuticsMD's is 1.8534. This would suggest that TherapeuticsMD's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.